Literature DB >> 1596891

Growth regulation of human renal carcinoma cells: role of transforming growth factor alpha.

I Atlas1, J Mendelsohn, J Baselga, W R Fair, H Masui, R Kumar.   

Abstract

Findings of increased numbers of epidermal growth factor receptors (EGF-R) and increased expression of transforming growth factor alpha (TGF-alpha) in surgical specimens of human renal cell carcinoma have led to the proposal that growth of these tumors may be regulated by TGF-alpha in an autocrine manner. In the studies presented here, we have examined this hypothesis using two human renal carcinoma cell lines, SKRC-4 and SKRC-29. We demonstrated that both SKRC-4 and SKRC-29 cells were growth stimulated by greater than 35% when cultured in the presence of TGF-alpha or EGF and were inhibited by 29% to 46% if cultured in the presence of anti-EGF-R monoclonal antibody 225. Treatment of cells with TGF-alpha enhanced the levels of expression of EGF-R mRNA and TGF-alpha mRNA. In addition, incubation of cells with monoclonal antibody 225 significantly elevated the levels of excreted TGF-alpha species in the culture medium. Our findings suggest that proliferation of human renal carcinoma cells may be regulated by endogenously produced TGF-alpha and that this regulatory pathway can be interrupted using antibody to its receptor, EGF-R.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1596891

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  ESMO pays tribute to Professor José Baselga.

Authors:  S Peters; J Tabernero; A Cervantes; S Banerjee; R Giuliani; F Lordick
Journal:  Immunooncol Technol       Date:  2021-04-27

2.  Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity.

Authors:  Jiabin An; Matthew B Rettig
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

3.  Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin.

Authors:  X Wu; Z Fan; H Masui; N Rosen; J Mendelsohn
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

4.  Intratumoral heterogeneity for expression of tyrosine kinase growth factor receptors in human colon cancer surgical specimens and orthotopic tumors.

Authors:  Toshio Kuwai; Toru Nakamura; Sun-Jin Kim; Takamitsu Sasaki; Yasuhiko Kitadai; Robert R Langley; Dominic Fan; Stanley R Hamilton; Isaiah J Fidler
Journal:  Am J Pathol       Date:  2008-01-17       Impact factor: 4.307

Review 5.  EGF receptor in neoplasia and metastasis.

Authors:  K Khazaie; V Schirrmacher; R B Lichtner
Journal:  Cancer Metastasis Rev       Date:  1993-09       Impact factor: 9.264

Review 6.  The epidermal growth factor receptor as a target for therapy in breast carcinoma.

Authors:  J Baselga; J Mendelsohn
Journal:  Breast Cancer Res Treat       Date:  1994-01       Impact factor: 4.872

7.  Expression of transforming growth factor beta in renal cell carcinoma and matched non-involved renal tissue.

Authors:  Dionisios Mitropoulos; Aspasia Kiroudi; Evangelia Christelli; Efraim Serafetinidis; Anastasios Zervas; Ioannis Anastasiou; Constantinos Dimopoulos
Journal:  Urol Res       Date:  2004-09-07

8.  Role of transforming growth factor-alpha in von Hippel--Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis.

Authors:  N de Paulsen; A Brychzy; M C Fournier; R D Klausner; J R Gnarra; A Pause; S Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-06       Impact factor: 11.205

Review 9.  Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results.

Authors:  S M Huang; P M Harari
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.651

Review 10.  Crossing paths in Human Renal Cell Carcinoma (hRCC).

Authors:  Guadalupe Aparicio Gallego; Vanessa Medina Villaamil; Enrique Grande; Isabel Santamarina Caínzos; Luís M Antón Aparicio
Journal:  Int J Mol Sci       Date:  2012-10-05       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.